Viatris Secures First-Ever GAD Treatment Approval in Japan with Effexor
核心洞察
Japan's Ministry of Health, Labour and Welfare approved Effexor SR for generalized anxiety disorder (搜索), making it the first and only approved GAD treatment in Japan.
The approval was based on a Phase 3 study showing significant superiority over placebo at 8 weeks with a p-value of 0.012 on the Hamilton Anxiety Rating Scale.
GAD affects 7.6% of Japan's general population according to recent studies, representing a significant unmet medical need in mental health care.
Japan's Ministry of Health, Labour and Welfare has approved Viatris Inc.'s Effexor SR (venlafaxine hydrochloride) for the treatment of generalized anxiety disorder (搜索) in adults, marking a significant milestone as the first and only approved treatment option for GAD in Japan. The approval addresses a long-standing unmet medical need in the country's mental health landscape.
Addressing Critical Treatment Gap
The approval fills a substantial void in Japan's treatment options for GAD, a highly disabling mental health condition that affects 7.6% of the general population according to recent studies. This prevalence rate suggests the condition may be significantly underdiagnosed, as the World Health Organization reports that only 2.6% of Japan's population will suffer from GAD in their lifetime.
"The approval of Effexor in Japan for generalized anxiety disorder (搜索) demonstrates the successful execution of our strategy to advance a differentiated and increasingly innovative portfolio in Japan, bringing forward value-added therapies that address a significant unmet need," said Philippe Martin, Viatris Chief R&D Officer.
Clinical Evidence Supporting Approval
The regulatory approval was based on a Phase 3 placebo-controlled, randomized, double-blind, multicenter study (Study B2411367) conducted specifically in Japanese patients with GAD. The trial achieved its primary objective, demonstrating superiority of venlafaxine's anxiolytic effects compared to placebo at 8 weeks, measured by changes in the Hamilton Anxiety Rating Scale (HAM-A) total score from baseline with a two-sided p-value of 0.012.
All seven secondary efficacy endpoints defined by the trial protocol were successfully met, reinforcing the drug's therapeutic benefit in this patient population.
Safety Profile Consistent with Global Experience
The safety analysis revealed a favorable tolerability profile consistent with Effexor's known safety characteristics in non-Japanese patients. Key safety findings included:
- Low discontinuation rates due to treatment-emergent adverse events (7.3% versus 1.7% for placebo)
- Only 3.9% of discontinuations were assessed as treatment-related, compared to 0.6% for placebo
- No serious treatment-emergent adverse events or severe intensity events were observed (0% versus 1.1% and 0.6% respectively for placebo)
The approval package also included results from a long-term extension study of venlafaxine in Japanese outpatients with GAD, providing additional safety and efficacy data.
Expanding Treatment Access
Effexor SR will be available in 37.5 mg and 75 mg capsule formulations for Japanese patients. The serotonin-noradrenaline reuptake inhibitor (搜索) (SNRI) was already approved in Japan for major depressive disorder (搜索) in adults and is currently approved to treat GAD in more than 80 countries worldwide.
"This approval marks the introduction of a new treatment option for adults in Japan living with GAD," said Corinne Le Goff, Viatris Chief Commercial Officer. "We look forward to leveraging our strong infrastructure and deep expertise in central nervous system therapies in Japan to bring access to this much needed treatment to patients."
Broader Portfolio Strategy
The Effexor approval represents part of Viatris' broader innovative portfolio expansion in Japan, which includes approved products such as Spydia (搜索) Nasal Spray (diazepam) for status epilepticus (搜索) treatment. The company's Japanese pipeline features investigational products including pitolisant for excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy, as well as ongoing pivotal Phase 3 trials for selatogrel in acute myocardial infarction (搜索), Nefecon (搜索) in IgA nephropathy (搜索), and cenerimod in systemic lupus erythematosus (搜索).